Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
14 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Asian stocks rose on Tuesday after a tech-fuelled rally lifted the Nasdaq to a record close, with a retreat in oil prices offering further support even as longer-dated Treasury yields hovered near multi-decade highs. The euro languished near 17-month lows after briefly touching $1.116 overnight, pressured by mounting f
Shares of Australia's CSL rose as much as 0.8% to A$178.340 after Jefferies raised its price target to A$161.50 from A$146.50 following a licensing deal with Alentis Therapeutics.
Jefferies raised Australia's CSL Ltd price target to A$161.50 from A$146.50 after the company licensed lixudebart, a Phase 2 anti-fibrotic antibody, from Swiss biotech Alentis Therapeutics. CSL will pay $355 million upfront, up to $1.2 billion in commercial milestones and fully fund development of the asset.
U.S. stocks look set to open in the red on Monday, with futures of the Dow Jones, S&P 500 and Nasdaq 100 indices falling following Friday’s higher close. Geopolitical uncertainty continues to weigh on markets after Iranian officials declared that the Strait of Hormuz will not fully reopen until Washington meets seven c
Australia's major banks are setting aside increased provisions for potential bad debts, citing shifts in consumer spending and early signs of weaker loan quality amid cost-of-living pressures, following the RBA's recent rate hike.
Liontown approved an A$389 million ($271.68 million) expansion of its Kathleen Valley lithium mine and lifted 2027 capital expenditure guidance to A$435 million-A$495 million from A$320 million-A$370 million; it expects 780,000 dmt/year spodumene concentrate output from FY2030.
European tech shares and Nasdaq futures advanced as Reuters reported Anthropic's planned public debut and a possible valuation above $2 trillion. Higher oil prices and multi-year highs in bond yields continued to weigh on markets.
JPMorgan upgraded IREN from Underweight to Overweight and lifted its price target from $46 to $65. BTIG maintained a Buy rating with a $80 price target.
D2L said second-quarter revenue rose 2% to $55.6 million and annual recurring revenue increased 5% to $223.4 million. Management also cited U.S. K-12 churn, revised full-year revenue growth guidance lower and left EBITDA guidance unchanged.
Braze reported fiscal second-quarter revenue of $227 million, up 26% year over year, and said non-GAAP operating margin improved by more than 600 basis points. It raised third-quarter and full-year revenue guidance.
Snowflake reported second-quarter product revenue of $1.49 billion, up 37% year over year, and raised FY27 product revenue guidance to $6.07 billion.
Australia spent heavily on imported technology, electric vehicles and energy in 2Q amid the Middle East crisis and AI facilitation efforts, but the growth composition was less encouraging than headlines suggest, says EY’s Cherelle Murphy.
U.S. futures were mixed Wednesday, with Dow Jones futures higher and S&P 500 and Nasdaq 100 futures slightly lower, as investors awaited Nvidia's second-quarter earnings and key inflation and GDP data.
Australia's household spending increases 1.3% month-over-month, exceeding estimates